Aurinia Pharmaceuticals (AUPH) Net Cash Flow (2020 - 2026)

Aurinia Pharmaceuticals has reported Net Cash Flow for 7 years, with the latest figure at -$39.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 130.55% year-over-year to -$39.2 million; the trailing twelve-month figure through Mar 2026 stood at -$25.4 million (down 1391.01% YoY), and the FY2025 full-year result was -$3.2 million, down 109.32% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$39.2 million, down from $7.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $46.3 million in Q4 2024, with the low at -$99.4 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$11.2 million across 5 years, with a median of -$5.2 million in 2023.
• The largest YoY upside for Net Cash Flow was 1768.08% in 2024 against a maximum downside of 325.72% in 2024.
• Aurinia Pharmaceuticals' Net Cash Flow stood at $8.1 million in 2022, then tumbled by 69.48% to $2.5 million in 2023, then surged by 1768.08% to $46.3 million in 2024, then sank by 84.83% to $7.0 million in 2025, then tumbled by 658.16% to -$39.2 million in 2026.
• The last three Net Cash Flow figures came in at -$39.2 million (Q1 2026), $7.0 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.